Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing competition and patent expiration increase urgency for Lilly | New Jersey and Delaware stores accused of selling unapproved tirzepatide-based products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Patent cliff: 5 blockbusters running out of road

1 April 2025 MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.

Americas

Eli Lilly takes further action over ‘dangerous’ diabetes drug fakes

25 June 2024 US drugmaker files six lawsuits over compounded tirzepatide products | At least five deaths associated with ‘generic’ Mounjaro, according to complaint | Fears over drug's 'unapproved' use for cosmetic weight loss.

Big Pharma

Pharmacy defends Eli Lilly off-label drug suit

11 April 2024 Diabetes drug is known for its off-label use as a weight-loss aid | Judge censures pharma giant for using state law instead of federal law in complaint | Development follows a wave of litigation involving Mounjaro.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

More on this story

Editor's picks

Editor's picks

More features